{"commentary":{"count":47,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":23,"podcast":12,"x_thread":12},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04136353\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DASL-HiCaP","nct_id":"NCT04136353","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dasl-hicap-nct04136353. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DASL-HiCaP","arms":[{"description":"Darolutamide 600mg (2 x 300mg tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.\n\nAll participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation.","label":"Darolutamide","type":"EXPERIMENTAL"},{"description":"Placebo (2 tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.\n\nAll participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation.","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":["Australian and New Zealand Urogenital and Prostate Cancer Trials Group","Bayer","Cancer Trials Ireland","Canadian Cancer Trials Group","Memorial Sloan Kettering Cancer Center","Prostate Cancer Clinical Trials Consortium"],"completion_date":{"date":"2028-07-31","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":1100,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Darolutamide","type":"DRUG"},{"name":"Placebo oral tablet","type":"DRUG"},{"name":"Luteinizing Hormone-Releasing Hormone Analog","type":"DRUG"},{"name":"External Beam Radiotherapy","type":"RADIATION"}],"last_update":"2026-05-06","lead_sponsor":"University of Sydney","official_title":"DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Metastasis-free survival","timeFrame":"Through study completion, an average of 5 years"}],"references":[],"start_date":{"date":"2020-03-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","url":"https://clinicaltrials.gov/study/NCT04136353"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dasl-hicap-nct04136353"}